Current Report Filing (8-k)
January 08 2018 - 7:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 8, 2018
MATINAS
BIOPHARMA HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-38022
|
|
46-3011414
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1545
Route 206 South, Suite 302
Bedminster,
New Jersey
|
|
07921
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(908) 443-1860
Not Applicable
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
[X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[X]
Item
8.01 Other Events.
On
January 8, 2018, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release to report that
the
Phase 2a clinical study of orally-administered MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis, which
is being conducted by the National Institutes of Health, or NIH, achieved statistical endpoint for success. Investigators from
the NIH have relayed to the Company positive data from a third patient enrolled in the Phase 2a clinical study. This third patient,
with long-standing azole resistant mucocutaneous candidiasis, met the primary endpoint of the Phase 2a study in achieving ≥
50% clinical response with treatment of MAT2203. MAT2203 was well tolerated with any adverse events observed being mild in severity
and unrelated to study drug. With this third positive response, the study has met its statistical hurdle for success. The press
release is attached hereto as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MATINAS
BIOPHARMA HOLDINGS, INC.
|
|
|
|
Dated:
January 8, 2018
|
By:
|
/s/
Roelof Rongen
|
|
Name:
|
Roelof Rongen
|
|
Title:
|
Chief Executive Officer
|
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024